Brief: Gossamer Bio Q4 EPS USD -0.15
13/03/2025 20:01
Mar 13 (Reuters) - Gossamer Bio Q4 net income USD -33.029 million. Q4 operating income USD -36.128 million Q4 operating expenses USD 45.507 million Q4 basic EPS USD -0.15
Recent news on Gossamer Bio
See all newsBrief: Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gossamer Bio - Board Approves Amendment And Restatement Of Bylaws Effective Sept 3, 2026 - SEC Filing